XENE Annual CFO
-$145.33 M
-$46.90 M-47.65%
31 December 2023
Summary:
As of January 23, 2025, XENE annual cash flow from operations is -$145.33 million, with the most recent change of -$46.90 million (-47.65%) on December 31, 2023. During the last 3 years, it has fallen by -$97.20 million (-201.98%). XENE annual CFO is now -418.89% below its all-time high of $45.57 million, reached on December 31, 2012.XENE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XENE Quarterly CFO
-$51.15 M
-$18.47 M-56.51%
30 September 2024
Summary:
As of January 23, 2025, XENE quarterly cash flow from operations is -$51.15 million, with the most recent change of -$18.47 million (-56.51%) on September 30, 2024. Over the past year, it has dropped by -$18.47 million (-56.51%). XENE quarterly CFO is now -358.49% below its all-time high of $19.79 million, reached on December 31, 2019.XENE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XENE TTM CFO
-$156.62 M
-$3.07 M-2.00%
30 September 2024
Summary:
As of January 23, 2025, XENE TTM cash flow from operations is -$156.62 million, with the most recent change of -$3.07 million (-2.00%) on September 30, 2024. Over the past year, it has dropped by -$3.07 million (-2.00%). XENE TTM CFO is now -4968.51% below its all-time high of $3.22 million, reached on September 30, 2014.XENE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XENE Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -47.6% | -56.5% | -2.0% |
| 3 y3 years | -202.0% | -54.0% | -19.8% |
| 5 y5 years | -318.5% | -54.0% | -19.8% |
XENE Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -109.1% | at low | -203.2% | at low | -133.0% | at low |
| 5 y | 5-year | -2982.9% | at low | -358.5% | at low | -3222.4% | at low |
| alltime | all time | -418.9% | at low | -358.5% | at low | -4968.5% | at low |
Xenon Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$51.15 M(+56.5%) | -$156.62 M(+2.0%) |
| June 2024 | - | -$32.68 M(-24.3%) | -$153.55 M(-0.4%) |
| Mar 2024 | - | -$43.18 M(+45.8%) | -$154.09 M(+6.0%) |
| Dec 2023 | -$145.33 M(+47.6%) | -$29.62 M(-38.4%) | -$145.33 M(-2.1%) |
| Sept 2023 | - | -$48.08 M(+44.7%) | -$148.44 M(+13.5%) |
| June 2023 | - | -$33.22 M(-3.5%) | -$130.77 M(+14.3%) |
| Mar 2023 | - | -$34.41 M(+5.1%) | -$114.41 M(+16.2%) |
| Dec 2022 | -$98.43 M(+41.6%) | -$32.73 M(+7.7%) | -$98.43 M(+13.9%) |
| Sept 2022 | - | -$30.40 M(+80.2%) | -$86.41 M(+21.7%) |
| June 2022 | - | -$16.87 M(-8.5%) | -$71.01 M(+5.6%) |
| Mar 2022 | - | -$18.43 M(-11.0%) | -$67.22 M(-3.3%) |
| Dec 2021 | -$69.50 M(+44.4%) | -$20.71 M(+38.0%) | -$69.50 M(+12.3%) |
| Sept 2021 | - | -$15.01 M(+14.8%) | -$61.91 M(+6.6%) |
| June 2021 | - | -$13.08 M(-36.9%) | -$58.05 M(+4.1%) |
| Mar 2021 | - | -$20.71 M(+57.9%) | -$55.77 M(+15.9%) |
| Dec 2020 | -$48.12 M(+920.9%) | -$13.11 M(+17.6%) | -$48.12 M(+216.1%) |
| Sept 2020 | - | -$11.15 M(+3.4%) | -$15.22 M(+36.8%) |
| June 2020 | - | -$10.79 M(-17.4%) | -$11.13 M(+22.5%) |
| Mar 2020 | - | -$13.07 M(-166.0%) | -$9.09 M(+92.7%) |
| Dec 2019 | -$4.71 M(-86.4%) | $19.79 M(-380.3%) | -$4.71 M(-85.1%) |
| Sept 2019 | - | -$7.06 M(-19.3%) | -$31.74 M(-17.4%) |
| June 2019 | - | -$8.75 M(+0.6%) | -$38.41 M(+9.1%) |
| Mar 2019 | - | -$8.70 M(+20.1%) | -$35.20 M(+1.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$34.72 M(+20.9%) | -$7.24 M(-47.2%) | -$34.72 M(+1.2%) |
| Sept 2018 | - | -$13.72 M(+147.8%) | -$34.32 M(+17.4%) |
| June 2018 | - | -$5.54 M(-32.6%) | -$29.22 M(-4.1%) |
| Mar 2018 | - | -$8.22 M(+20.2%) | -$30.48 M(+6.1%) |
| Dec 2017 | -$28.73 M(+46.8%) | -$6.84 M(-20.7%) | -$28.73 M(+8.2%) |
| Sept 2017 | - | -$8.63 M(+26.8%) | -$26.56 M(+18.3%) |
| June 2017 | - | -$6.80 M(+5.3%) | -$22.46 M(+6.5%) |
| Mar 2017 | - | -$6.46 M(+38.3%) | -$21.08 M(+7.7%) |
| Dec 2016 | -$19.57 M(+8.1%) | -$4.67 M(+3.2%) | -$19.57 M(-2.9%) |
| Sept 2016 | - | -$4.52 M(-16.7%) | -$20.14 M(-1.8%) |
| June 2016 | - | -$5.43 M(+9.8%) | -$20.50 M(+17.2%) |
| Mar 2016 | - | -$4.94 M(-5.8%) | -$17.50 M(-3.3%) |
| Dec 2015 | -$18.10 M(-6905.6%) | -$5.25 M(+7.4%) | -$18.10 M(+14.5%) |
| Sept 2015 | - | -$4.88 M(+101.5%) | -$15.81 M(+240.8%) |
| June 2015 | - | -$2.42 M(-56.3%) | -$4.64 M(+4.5%) |
| Mar 2015 | - | -$5.55 M(+88.0%) | -$4.44 M(-1768.8%) |
| Dec 2014 | $266.00 K(-108.0%) | -$2.95 M(-147.0%) | $266.00 K(-91.7%) |
| Sept 2014 | - | $6.28 M(-382.4%) | $3.22 M(-204.9%) |
| June 2014 | - | -$2.23 M(+164.3%) | -$3.07 M(+264.3%) |
| Mar 2014 | - | -$842.00 K | -$842.00 K |
| Dec 2013 | -$3.32 M(-107.3%) | - | - |
| Dec 2012 | $45.57 M(-432.9%) | - | - |
| Dec 2011 | -$13.69 M | - | - |
FAQ
- What is Xenon Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals annual CFO year-on-year change?
- What is Xenon Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals quarterly CFO year-on-year change?
- What is Xenon Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals TTM CFO year-on-year change?
What is Xenon Pharmaceuticals annual cash flow from operations?
The current annual CFO of XENE is -$145.33 M
What is the all time high annual CFO for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high annual cash flow from operations is $45.57 M
What is Xenon Pharmaceuticals annual CFO year-on-year change?
Over the past year, XENE annual cash flow from operations has changed by -$46.90 M (-47.65%)
What is Xenon Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of XENE is -$51.15 M
What is the all time high quarterly CFO for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high quarterly cash flow from operations is $19.79 M
What is Xenon Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, XENE quarterly cash flow from operations has changed by -$18.47 M (-56.51%)
What is Xenon Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of XENE is -$156.62 M
What is the all time high TTM CFO for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high TTM cash flow from operations is $3.22 M
What is Xenon Pharmaceuticals TTM CFO year-on-year change?
Over the past year, XENE TTM cash flow from operations has changed by -$3.07 M (-2.00%)